Advertisement

In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells

  • Amir Asgari
  • Sedigheh Sharifzadeh
  • Abbas Ghaderi
  • Ahmad Hosseini
  • Amin RamezaniEmail author
Original Article

Abstract

Targeting erb-b2 receptor tyrosine kinase 2 (ERBB2) using the combination of Trastuzumab and Pertuzumab has demonstrated promising results in breast cancer therapy. It has further been revealed that interleukin-2 (IL-2) can activate Natural Killer cells (NK cells) and elevate their cytotoxic potency against tumor cells. In this study, we explored the cytotoxic effect of recombinant human IL-2 in combination with Trastuzumab and Pertuzumab on the ERBB2 positive (SK-BR-3) and negative (MDA-MB-231) breast cancer cell lines. The cytotoxicity level of IL-2 activated NK cells (approximately 75%) were significantly higher than untreated cells (approximately 55%) in the presence of Trastuzumab and Pertuzumab against SK-BR-3 cells, while no difference was observed in the case of MDA-MB-231 cells (about 15%).

Keywords

Breast cancer Immunotherapy Trastuzumab Pertuzumab Interleukin 2 

Notes

Acknowledgements

The study was a part of the M.Sc thesis project of Amir Asgari, Department of Medical Biotechnology, Shiraz University of Medical Sciences (Grant No. 15652). In addition, this work was supported by Shiraz Institute for Cancer Research (Grant No. ICR-100-509)

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest regarding this manuscript.

References

  1. 1.
    Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11(2):263–275Google Scholar
  2. 2.
    Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L et al (2015) The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer—a systematic review. Breast Cancer Res 17(1):140Google Scholar
  3. 3.
    Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H et al (2011) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119Google Scholar
  4. 4.
    Makhoul I, Atiq M, Alwbari A, Kieber-Emmons T (2018) Breast cancer immunotherapy: an update. Breast Cancer 12:1178223418774802Google Scholar
  5. 5.
    McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M et al (2009) HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9:433Google Scholar
  6. 6.
    Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V (2014) Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist 19(8):805–813Google Scholar
  7. 7.
    Ramezani A, Mahmoudi Maymand E, Yazdanpanah-Samani M, Hosseini A, Toghraie FS, Ghaderi A (2017) Improving pertuzumab production by gene optimization and proper signal peptide selection. Protein Expr Purif 135:24–32Google Scholar
  8. 8.
    Ramezani A, Ghaderi A (2018) Using a dihydrofolate reductase-based strategy for producing the biosimilar version of pertuzumab in CHO-S cells. Monoclon Antib Immunodiagn Immunother 37(1):26–37Google Scholar
  9. 9.
    Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595Google Scholar
  10. 10.
    Dutcher JP (2002) Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park, NY). 16(11 Suppl 13):4–10Google Scholar
  11. 11.
    Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ et al (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31(10):3016–3025Google Scholar
  12. 12.
    Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D et al (2015) Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 25(2):208–224Google Scholar
  13. 13.
    Li X, Lu P, Li B, Zhang W, Yang R, Chu Y et al (2017) Interleukin 2 and interleukin 10 function synergistically to promote CD8+ T cell cytotoxicity, which is suppressed by regulatory T cells in breast cancer. Int J Biochem Cell Biol 87:1–7Google Scholar
  14. 14.
    Wang A, Lu SD, Mark DF (1984) Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science 224(4656):1431Google Scholar
  15. 15.
    Liang S-M, Allet B, Rose K, Hirschi M, Liang C-M, Thatcher DR (1985) Characterization of human interleukin 2 derived from Escherichia coli. Biochem J 229(2):429–439Google Scholar
  16. 16.
    Sengupta P, Meena K, Mukherjee R, Jain SK, Maithal K (2008) Optimized conditions for high-level expression and purification of recombinant human interleukin-2 in E. coli. Indian J Biochem Biophys 45(2):91–97Google Scholar
  17. 17.
    Massiah MA, Wright KM, Du H (2016) Obtaining soluble folded proteins from inclusion bodies using sarkosyl, triton X-100, and CHAPS: application to LB and M9 minimal media. Curr Protoc Protein Sci.  https://doi.org/10.1002/0471140864.ps0613s84 Google Scholar
  18. 18.
    Lord JD, McIntosh BC, Greenberg PD, Nelson BH (2000) The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol 164(5):2533–2541Google Scholar
  19. 19.
    Shatrova AN, Mityushova EV, Vassilieva IO, Aksenov ND, Zenin VV, Nikolsky NN et al (2016) Time-dependent regulation of IL-2R α-chain (CD25) expression by TCR signal strength and IL-2-induced STAT5 signaling in activated human blood T lymphocytes. PLoS ONE 11(12):e0167215-eGoogle Scholar
  20. 20.
    Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA (1998) Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 46(6):318–326Google Scholar
  21. 21.
    Ahn YO, Kim S, Kim TM, Song EY, Park MH, Heo DS (2013) Irradiated and activated autologous PBMCs induce expansion of highly cytotoxic human NK cells in vitro. J Immunother 36(7):373–381Google Scholar
  22. 22.
    Tashnizi AH, Habibagahi M, Majidi J, Razmkhah M, Talei A, Ghaderi A et al (2014) Th1 and Th2 cytokine gene expression in the peripheral blood of breast cancer patients compared to controls. Middle East J Cancer 5(3):119–127Google Scholar
  23. 23.
    García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M (2004) Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res 6(1):R1–R7Google Scholar
  24. 24.
    Mamessier E, Pradel LC, Thibult ML, Drevet C, Zouine A, Jacquemier J et al (2013) Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol 190(5):2424–2436Google Scholar
  25. 25.
    Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U et al (2009) The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res 29(7):2445–2451Google Scholar
  26. 26.
    Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, Kawaguchi Y et al (2010) Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer 103(4):552–559Google Scholar
  27. 27.
    Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64(7):2343–2346Google Scholar
  28. 28.
    Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28(7):1138–1144Google Scholar
  29. 29.
    Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U et al (2008) Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 14(9):2710–2716Google Scholar
  30. 30.
    Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32Google Scholar
  31. 31.
    Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P et al (2009) A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat 117(1):83–89Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Division of Medical Biotechnology, Department of Laboratory Sciences, School of Paramedical SciencesShiraz University of Medical SciencesShirazIran
  2. 2.Shiraz Institute for Cancer Research, School of MedicineShiraz University of Medical SciencesShirazIran
  3. 3.Department of Immunology, School of MedicineShiraz University of Medical SciencesShirazIran
  4. 4.Department of Medical Biotechnology, School of Advanced Medical Sciences and TechnologiesShiraz University of Medical SciencesShirazIran

Personalised recommendations